Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SVA · NASDAQ · Pharmaceutical Preparations · Foreign private issuer
Sinovac Biotech (SVA) · oqro.io/stocks/SVA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Beijing. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Revenue, fiscal 2025
$386M
+6.8% vs the year before
Net income
Not reported
As reported in the annual filing
Shares outstanding
71.9M
As of Dec 31, 2025
In fiscal 2025 the company spent $3.53B on dividends. Cash actually paid, from its cash-flow statement.
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
No open-market purchase by an insider of Sinovac Biotech is on record in SEC filings since 2006.
No open-market sale by an insider of Sinovac Biotech (SVA) was filed with the SEC in the last 90 days.
No trade in Sinovac Biotech (SVA) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
11 active phase 3 trials and 2 active phase 2 trials led by this company, mostly in epidemic meningitis, rabies, rabies (healthy volunteers). The ones with the nearest registered primary completion date still ahead:
5 trials have a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
On the public record for Sinovac Biotech over the 12 months to Nov 14, 2026: 9 clinical trials.